How High Will Dollar General Stock Go?
Shares of Dollar General (NYSE:DG) have risen significantly in recent…
Sell
38
DVAX Quote, Financials, Valuation and Earnings
Last price:
$10.36
Seasonality move
:
10.79%
Day range:
$10.00 - $10.25
52-week range:
$9.22 - $14.63
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
4.92x
P/B ratio:
2.32x
Volume:
1.4M
Avg. volume:
2.2M
1-year change:
-16.54%
Market cap:
$1.2B
Revenue:
$277.2M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.28, Dynavax Technologies has an estimated upside of 127.3% from its current price of $10.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.10 representing 100% downside risk from its current price of $10.24.
Fair Value
-
According to the consensus of 2 analysts, Dynavax Technologies has 127.3% upside to fair value with a price target of $23.28 per share.
DVAX vs. S&P 500
-
Over the past 5 trading days, Dynavax Technologies has overperformed the S&P 500 by 3.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dynavax Technologies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dynavax Technologies has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Dynavax Technologies reported revenues of $68.2M.
Earnings Growth
-
Dynavax Technologies has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dynavax Technologies reported earnings per share of -$0.77.
Enterprise value:
828.8M
EV / Invested capital:
1.05x
Price / LTM sales:
4.92x
EV / EBIT:
19.02x
EV / Revenue:
2.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
15.34x
Price / Operating cash flow:
26.85x
Enterprise value / EBITDA:
15.67x
Gross Profit (TTM):
$242.4M
Return On Assets:
-6.01%
Net Income Margin (TTM):
-20.39%
Return On Equity:
-9.78%
Return On Invested Capital:
-7.11%
Operating Margin:
-18.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $655.6M | $236.1M | $294.6M | $50.8M | $68.2M | |
| Gross Profit | $418.7M | $189.7M | $242.4M | $39.8M | $54.4M | |
| Operating Income | $233.8M | -$25.5M | $988K | -$17.8M | -$12.7M | |
| EBITDA | $251M | $22.2M | -$40.6M | -$8.1M | -$94.4M | |
| Diluted EPS | $1.56 | $0.06 | -$0.52 | -$0.07 | -$0.77 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $427.5M | $940.5M | $830.1M | $851.3M | $816M | |
| Total Assets | $490.1M | $1B | $969.9M | $986.6M | $945.9M | |
| Current Liabilities | $109.4M | $466.2M | $91.5M | $56M | $68.4M | |
| Total Liabilities | $390.4M | $721.5M | $406.2M | $368.1M | $415M | |
| Total Equity | $99.8M | $287.5M | $563.7M | $618.5M | $530.9M | |
| Total Debt | $179.9M | $220.8M | $221.9M | $223M | $260.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $140.8M | $56.3M | $63.6M | -$16.7M | -$19.6M | |
| Cash From Investing | -$151.8M | -$98.8M | -$14M | $2.8M | $6.9M | |
| Cash From Financing | $6.1M | $273K | -$129.7M | -$4.2M | -$31.9M | |
| Free Cash Flow | $133.7M | $52.7M | $54M | -$17.4M | -$23.6M | |
DVAX
Sector
Market Cap
$1.2B
$33.9M
Price % of 52-Week High
69.99%
46.67%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-16.54%
-37.84%
Beta (5-Year)
1.065
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.87
200-day SMA
Sell
Level
$11.94
Bollinger Bands (100)
Sell
Level
10.53 - 13.55
Chaikin Money Flow
Sell
Level
-7.3M
20-day SMA
Buy
Level
$9.80
Relative Strength Index (RSI14)
Buy
Level
50.76
ADX Line
Sell
Level
23.69
Williams %R
Neutral
Level
-21.0526
50-day SMA
Sell
Level
$10.85
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-10M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5302)
Buy
CA Score
(Annual)
Level (0.3412)
Buy
Beneish M-Score
(Annual)
Level (-2.5958)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.9658)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Stock Forecast FAQ
In the current month, DVAX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DVAX average analyst price target in the past 3 months is $23.28.
-
Where Will Dynavax Technologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dynavax Technologies share price will rise to $23.28 per share over the next 12 months.
-
What Do Analysts Say About Dynavax Technologies?
Analysts are divided on their view about Dynavax Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dynavax Technologies is a Sell and believe this share price will drop from its current level to $11.10.
-
What Is Dynavax Technologies's Price Target?
The price target for Dynavax Technologies over the next 1-year time period is forecast to be $23.28 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DVAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dynavax Technologies is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DVAX?
You can purchase shares of Dynavax Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dynavax Technologies shares.
-
What Is The Dynavax Technologies Share Price Today?
Dynavax Technologies was last trading at $10.36 per share. This represents the most recent stock quote for Dynavax Technologies. Yesterday, Dynavax Technologies closed at $10.24 per share.
-
How To Buy Dynavax Technologies Stock Online?
In order to purchase Dynavax Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can Planet Labs Go Now?
Planet Labs (NYSE:PL) has been a much-talked-about stock for years,…
Where Will Broadcom Stock Be in 5 Years?
Broadcom (NASDAQ:AVGO) has soared by over 75 percent over the…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Alerts
Sell
19
LULU alert for Jun 9
Lululemon Athletica [LULU] is down 1.27% over the past day.
Sell
46
DOCU alert for Jun 9
Docusign [DOCU] is up 4% over the past day.
Buy
66
BYRN alert for Jun 9
Byrna Technologies [BYRN] is down 2.52% over the past day.
